NO20020254L - Novel carboxylic acid derivatives with 5,6-substituted pyrimidine ring, preparation and use thereof as endothelin receptor antagonists - Google Patents

Novel carboxylic acid derivatives with 5,6-substituted pyrimidine ring, preparation and use thereof as endothelin receptor antagonists

Info

Publication number
NO20020254L
NO20020254L NO20020254A NO20020254A NO20020254L NO 20020254 L NO20020254 L NO 20020254L NO 20020254 A NO20020254 A NO 20020254A NO 20020254 A NO20020254 A NO 20020254A NO 20020254 L NO20020254 L NO 20020254L
Authority
NO
Norway
Prior art keywords
preparation
carboxylic acid
acid derivatives
receptor antagonists
pyrimidine ring
Prior art date
Application number
NO20020254A
Other languages
Norwegian (no)
Other versions
NO20020254D0 (en
Inventor
Wilhelm Amberg
Georg Kettschau
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20020254D0 publication Critical patent/NO20020254D0/en
Publication of NO20020254L publication Critical patent/NO20020254L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
NO20020254A 1999-07-20 2002-01-17 Novel carboxylic acid derivatives with 5,6-substituted pyrimidine ring, preparation and use thereof as endothelin receptor antagonists NO20020254L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19933164A DE19933164A1 (en) 1999-07-20 1999-07-20 New carboxylic acid derivatives with 5,6 substituted pyrimidine ring, their production and use as endothelin receptor antagonists
PCT/EP2000/006293 WO2001005771A1 (en) 1999-07-20 2000-07-05 Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists

Publications (2)

Publication Number Publication Date
NO20020254D0 NO20020254D0 (en) 2002-01-17
NO20020254L true NO20020254L (en) 2002-02-20

Family

ID=7914884

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020254A NO20020254L (en) 1999-07-20 2002-01-17 Novel carboxylic acid derivatives with 5,6-substituted pyrimidine ring, preparation and use thereof as endothelin receptor antagonists

Country Status (21)

Country Link
EP (1) EP1196394A1 (en)
JP (1) JP2003505377A (en)
KR (1) KR20020019550A (en)
CN (1) CN1367778A (en)
AR (1) AR030026A1 (en)
AU (1) AU6561500A (en)
BG (1) BG106321A (en)
BR (1) BR0012592A (en)
CA (1) CA2379545A1 (en)
CZ (1) CZ2002190A3 (en)
DE (1) DE19933164A1 (en)
HU (1) HUP0202646A3 (en)
IL (1) IL147666A0 (en)
MX (1) MXPA02000616A (en)
NO (1) NO20020254L (en)
PL (1) PL353165A1 (en)
SK (1) SK772002A3 (en)
TR (1) TR200200622T2 (en)
TW (1) TW555749B (en)
WO (1) WO2001005771A1 (en)
ZA (1) ZA200200333B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5531097B2 (en) * 2009-07-10 2014-06-25 カディラ・ヘルスケア・リミテッド Improved process for preparing ambrisentan and novel intermediates thereof
US20130060031A1 (en) 2010-03-15 2013-03-07 Natco Pharma Limited Process for the preparation of highly pure ambrisentan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (en) * 1996-09-05 1998-03-12 Basf Ag New carboxylic acid derivatives, their production and use as mixed ET¶A¶ / ET¶B¶ receptor antagonists
EP1027338A2 (en) * 1997-10-31 2000-08-16 Basf Aktiengesellschaft New carboxylic acid derivatives, carrying amido side-chains; production and use as endothelin receptor antagonists

Also Published As

Publication number Publication date
CZ2002190A3 (en) 2003-08-13
DE19933164A1 (en) 2001-01-25
PL353165A1 (en) 2003-10-20
KR20020019550A (en) 2002-03-12
AR030026A1 (en) 2003-08-13
BG106321A (en) 2002-08-30
JP2003505377A (en) 2003-02-12
EP1196394A1 (en) 2002-04-17
HUP0202646A2 (en) 2003-02-28
HUP0202646A3 (en) 2003-03-28
CN1367778A (en) 2002-09-04
TW555749B (en) 2003-10-01
TR200200622T2 (en) 2002-06-21
IL147666A0 (en) 2002-08-14
AU6561500A (en) 2001-02-05
NO20020254D0 (en) 2002-01-17
ZA200200333B (en) 2003-04-30
SK772002A3 (en) 2003-01-09
MXPA02000616A (en) 2002-08-30
WO2001005771A1 (en) 2001-01-25
BR0012592A (en) 2002-05-28
CA2379545A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
EP1349839B8 (en) Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
LTPA2015036I1 (en) 4-PHENYLPYRIDINE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS
NO20014098D0 (en) 3-phenylpyridine derivatives and their use as NK-1 receptor antagonists
DK1163264T3 (en) New LHRH antagonists with improved solubility properties
NO20002124D0 (en) Novel Carboxylic Acid Derivatives with Amide Side Chains, Their Preparation and Use as Endothelin Receptor Antagonists
NO20014224D0 (en) 4-heterocyclysulfonamidyl-6-methoxy-5- (2-methoxy-phenoxy) -2-pyridyl-pyrimidine derivatives, preparation thereof and use as endothelin receptor antagonists
NO992976L (en) Heterocyclic carboxylic acid derivatives, preparation and use thereof as endothelin receptor antagonists
ZA985277B (en) Novel ß-amino and ß-azido carboxylic and acid derivatives, their preparation and use as endothelin receptor antagonists.
NO20020254D0 (en) Novel carboxylic acid derivatives with 5,6-substituted pyrimidine ring, preparation and use thereof as endothelin receptor antagonists
NO20001077D0 (en) Novel Carboxylic Acid Derivatives, Their Preparation and Use as Mixed ETA / ETB Endothelin Receptor Antagonists
PL375263A1 (en) 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
NO20010622D0 (en) Novel carboxylic acid derivatives bearing keto side chains, their preparation and their use as endothelin receptor antagonists
HK1042095A1 (en) New b-amide and b-sulfonamide carboxylic acid derivatives, their preparation and their use as endothelin receptor antagonists
ZA9810425B (en) Novel heterocyclically substituted Ó-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists.
IL137038A0 (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
AU2001231744A1 (en) Novel carboxylic acid derivatives containing alkyl substituted triazines, production of the same and use thereof as endothelin receptor antagonists
HK1047102A1 (en) Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists
ZA988053B (en) Novel carboxylic acid derivatives, their preparation and use as mixed ETA/ETB receptor antagonists.
ZA9711305B (en) Heterocyclic carboxylic acid derivatives their preparation and use as endothelin receptor antagonists
ITMI20001667A0 (en) DERIVATIVES OF 2- OR 3-TENOIC ACID WITH GLUTAMATE RECEPTOR ANTAGONIST ACTIVITY.
DK1200402T3 (en) Substituted 1,5-dihydropyrrol-2-one derivatives acting as NMDA receptor antagonists for the treatment of pain conditions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application